Do I still need a prior authorization for Zepbound after October 1?

In most plans, yes. Preferred formulary status generally means lower cost and easier access, not the removal of prior authorization. Standard CVS Caremark PA criteria for weight-loss Zepbound typically require BMI of 30 or higher, or BMI of 27 or higher with a documented comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea, plus documentation of a weight-management program. If you were previously switched from Zepbound to Wegovy under the July 2025 change, expect to submit a new PA if you and your clinician decide to switch back.

How does the $25 a month Zepbound price work?

The $25 monthly price is a manufacturer copay program from Eli Lilly for eligible commercially insured patients whose plan covers Zepbound. Eligibility rules, income limits, and annual caps are set by the manufacturer and change over time. If your plan does not cover Zepbound, the copay card generally cannot reduce your cost to $25. Confirm current terms and eligibility directly on the Lilly Zepbound patient program page before you count on that price. Government insurance plans, including Medicare and Medicaid, are usually excluded from commercial copay cards.

What if my employer plan does not cover Zepbound in 2027?

You have several options. Ask HR whether a medical-necessity exception exists based on documented comorbid conditions. Ask when the plan is next reviewed and whether the weight-loss carve-out can be revisited. If immediate treatment matters, cash-pay paths are available: Lilly self-pay Zepbound single-dose vials, brand-name Wegovy through manufacturer programs, or compounded tirzepatide through licensed telehealth practices. Compounded medications are not FDA-approved products; they are prepared by licensed compounding pharmacies under physician supervision. HSA and FSA funds can typically be used for prescribed GLP-1 medications regardless of the pathway.

CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment

Q: What did CVS Caremark actually announce on May 28, 2026?

CVS Caremark announced that Zepbound (tirzepatide) will return to its commercial formulary templates as an additional preferred option effective October 1, 2026. Wegovy retains preferred status. On October 1, both drugs sit on the same formulary tier with the same copay for plans that follow the standard template. The change affects the standard commercial formulary template, which CVS says covers roughly 25 to 30 million Americans. Each plan sponsor — usually the employer — can still customize coverage or opt out.

Q: Does October 1, 2026 automatically mean my plan covers Zepbound?

No. Preferred status on the CVS Caremark template is an option that individual plan sponsors elect. Employers that use the standard template can still choose to exclude weight-loss GLP-1s entirely, keep Wegovy as the only preferred option, or add utilization management rules such as prior authorization, step therapy, and BMI thresholds. The only way to know is to ask your HR benefits team, then confirm with CVS Caremark member services on the number on the back of your insurance card.

What actually changed on October 1

On May 28, 2026, CVS Health announced that Zepbound (tirzepatide) would return to CVS Caremark’s standard commercial formulary templates as an additional preferred option effective October 1, 2026. Wegovy (semaglutide) keeps its preferred status. Starting October 1, both drugs sit on the same formulary tier with the same copay for plans that follow the standard template. That reverses the July 2025 change that dropped Zepbound in favor of Wegovy as the single preferred weight-loss GLP-1.

The scale is significant. CVS Caremark told The Boston Globe the standard commercial formulary template covers roughly 25 to 30 million Americans. On the same day, CVS also removed the new-to-market block on Foundayo (orforglipron), an oral GLP-1 approved for chronic weight management, effective June 1, 2026 for plans that elect to cover it.

Two things this change is not: it is not an FDA action, and it is not a universal coverage mandate. It is a formulary election that a pharmacy benefit manager offers to plan sponsors, who are usually employers. The rest of this guide walks through the practical difference between “the option exists” and “your plan actually covers it,” and gives you the exact questions to ask HR while your 2027 open enrollment window is still open.

Why October 1 does not automatically mean your plan covers Zepbound

Preferred status on the CVS Caremark template is an option, not a mandate. Employers that use the standard template can still choose to exclude weight-loss GLP-1s entirely, keep Wegovy as the only preferred option, or add utilization management rules that make coverage difficult to access in practice. CVS said so directly: plan sponsors that adopt the template “retain discretion to customize coverage.” That single sentence is the entire reason this article exists.

Three scenarios are common for October 1 and 2027 plan years:

Your employer follows the standard template and elects both. You gain access to Zepbound at the same tier and copay as Wegovy, subject to prior authorization. Manufacturer copay assistance may apply.
Your employer follows the template but keeps a weight-loss carve-out. Zepbound is technically on the formulary, but your plan does not cover any GLP-1 for weight management, so the copay is retail price or you cannot fill the prescription at all through the plan.
Your employer uses a customized formulary. The template change does not affect you directly. Your plan’s benefits team decides independently whether to add Zepbound, and the decision may not happen for the 2027 plan year at all.

You cannot tell which scenario applies to you by reading the news. You have to ask HR and confirm in writing. That is what the questions below are for.

The 6 questions to ask HR before your 2027 election

Ask these in writing whenever possible — email or HR-portal message — so you have a paper trail. If HR responds verbally, follow up with a short email summarizing the answer and asking them to confirm. Coverage disputes later in the year are resolved by paperwork, not by memory.

1. Does the 2027 plan cover Zepbound (tirzepatide) for weight management, not just Wegovy?

This is the whole ballgame. Get a straight yes or no on Zepbound specifically. Do not accept “we cover GLP-1s” as an answer — ask which specific medications, under which diagnosis codes, and effective on which date. The October 1, 2026 CVS Caremark change is at the formulary-template level; whether it flows through to your specific plan depends entirely on your employer’s election.

2. Did the employer opt into or out of the standard CVS Caremark formulary template for 2027?

If yes, the October 1 change likely applies. If the plan uses a customized formulary, the change may not apply. This question exists because HR sometimes cannot answer it without going back to the benefits broker or PBM; a written follow-up is often required. Ask for the plan year and effective date of any coverage change, not just a general answer.

3. Is there a weight-loss exclusion or carve-out in the 2027 plan document?

If a formal exclusion exists, adding Zepbound to the formulary at the PBM level does not help — the medication is not covered under your plan regardless. Ask HR to point you to the exact section of the summary plan description that addresses weight-loss medication coverage. If a carve-out exists, ask whether a medical-necessity exception process is available for documented comorbid conditions such as type 2 diabetes, obstructive sleep apnea, or cardiovascular risk.

4. What are the prior-authorization criteria and expected turnaround?

Preferred status is not a bypass of prior authorization. Standard CVS Caremark PA criteria for weight-loss Zepbound typically require BMI of 30 or higher, or BMI of 27 or higher with a documented comorbidity, plus documentation of a supervised weight-management program. Ask for the exact written criteria your plan will use in 2027 and how long a decision typically takes. Standard commercial PAs are usually decided within 15 to 30 business days.

5. If I am currently on Wegovy under this plan, what happens if I want to switch to Zepbound?

Members who were previously on Zepbound and switched to Wegovy under the July 2025 change are not automatically transitioned back. Your clinician generally needs to submit a new prior authorization with clinical justification. “Patient preference” alone is often not enough — documentation typically needs to reference side effects, insufficient response, or another clinical rationale. Ask HR and CVS Caremark member services what documentation your plan will require.

6. What is my expected out-of-pocket cost with the $25 copay program applied?

Lilly and CVS Caremark have publicized a $25-per-month copay for eligible commercially insured patients. That price is not automatic. It requires plan coverage of Zepbound, patient eligibility for the manufacturer copay card, and no plan-level accumulator or maximizer program that blocks copay card credit. Ask HR whether the 2027 plan is copay-accumulator or copay-maximizer, and confirm your specific out-of-pocket cost with CVS Caremark before you count on $25.

The $25 a month price: what actually qualifies

A lot of the headlines around the CVS Caremark announcement led with “$25 per month.” That number comes from an Eli Lilly manufacturer copay program for commercially insured patients whose plan covers Zepbound. It is not a CVS price, it is not universal, and it does not apply if your plan does not cover the medication.

The eligibility structure has several layers you should know about before you assume the $25 price is yours:

Commercial insurance only. Government insurance — Medicare, Medicaid, TRICARE, VA, and similar programs — is generally excluded from manufacturer copay cards regardless of the plan’s formulary status.
Coverage of Zepbound required. If your plan does not cover Zepbound for weight management, the copay card generally cannot reduce your cost to $25. Cash price without coverage runs into the four figures at retail.
Accumulator and maximizer programs. Some employer plans do not let manufacturer copay card payments count toward your deductible or out-of-pocket max. That can quietly change your annual total even when your monthly copay looks fine.
Program terms change. Eligibility rules, income caps, and annual maximums are set by the manufacturer and revised periodically. Verify current terms directly on the Lilly Zepbound patient program page before making a coverage decision based on the $25 figure.

If any of those layers fails for you, the $25 price does not apply. That does not necessarily mean Zepbound is out of reach — it means the honest number for you is different, and you need to know what it is before open enrollment closes.

Prior authorization still applies

Preferred formulary status means Zepbound sits on the same tier with the same copay as Wegovy. It does not mean prior authorization goes away. For weight-loss Zepbound, most CVS Caremark plans continue to require:

BMI of 30 or higher, or BMI of 27 or higher with one or more weight-related comorbid conditions such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Age 18 or older.
Documentation of a supervised weight-management program — often a six-month lifestyle intervention with dietary changes and physical activity.
Clinician attestation of medical necessity for the specific patient.

If you were on Zepbound in 2025 and were forced to switch to Wegovy under the July 2025 formulary change, your old PA was typically transitioned to Wegovy at the time. It does not carry back to Zepbound automatically. If you and your clinician decide switching back is medically appropriate on or after October 1, 2026, expect a new PA submission with fresh clinical documentation. If that PA is denied, the appeal process is still available — our GLP-1 prior authorization denial checklist walks through the questions to ask your insurer and what your clinician needs to submit.

If your plan does not elect Zepbound for 2027

If the answers from HR add up to “this is not covered on our 2027 plan,” you have practical options that do not require you to wait for the next open enrollment window.

Brand-name direct-pay programs

Eli Lilly’s direct-pay program for Zepbound single-dose vials publishes tiered pricing starting around $299 per month at the 2.5 mg dose and rising with higher doses; refill pricing is higher if the required check-in cadence is missed. LillyDirect also offers Zepbound in vial format at tiered dose-based pricing. Novo Nordisk offers various savings pathways for Wegovy, and eligibility depends on insurance status. Verify current terms directly on the manufacturer sites before deciding. These are legitimate paths for patients who want brand-name FDA-approved medication and can absorb the higher monthly cost.

Compounded telehealth

Cash-pay compounded tirzepatide through telehealth practices typically ranges from about $232 to $449 per month depending on the provider. Some practices layer a separate membership fee on top of the medication price. Some do not. Compounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision, and compounded medications are not FDA-approved products. If you are comparing providers, our full telehealth pricing comparison walks through what Henry Meds, Mochi, Ro Body, LillyDirect, and SkinnyVIP each charge and what is included.

HSA and FSA funds

GLP-1 medications prescribed by a licensed clinician are generally eligible expenses for both Health Savings Accounts and Flexible Spending Accounts because they are prescription medications. This applies whether you go the brand-name route or the compounded route. If you are re-electing HSA or FSA contributions during open enrollment, factor annual GLP-1 spending into the number. Our HSA and FSA guide for GLP-1 costs covers what qualifies and what documentation to keep.

How SkinnyVIP handles this

SkinnyVIP lists a $695 three-month plan (about $232 per month) or a $350 single-month plan. The stated price applies across the 2.5 mg to 15 mg dose range — it does not rise solely because the dose changes. There is no membership fee and no auto-renewal. Consultation, medication, supplies, and shipping are included. No insurance paperwork is required from you. Current details are on the SkinnyVIP pricing page.

SkinnyVIP offers telemedicine via a nationwide telemedicine platform. A licensed clinician reviews your health history to determine whether treatment is appropriate; prescription is not guaranteed. SkinnyVIP does not itself prescribe — a licensed clinician does. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). If you want to see the clinical pathway alongside the numbers, review the $232/mo compounded tirzepatide overview.